MedTrace Logo

A Single and Multiple Dose Study to Evaluate the Safety and Effects of Inhaled ICF001 Dry Powder in Healthy Participants

NCT07804628 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-09-04

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristics of ICF001 following inhaled administration of single and multiple ascending doses in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ICF001

ICF001 capsule-based inhalation powders.

DRUG

Placebo

Matching-placebo capsule-based inhalation powders.

Sponsors & Collaborators

  • VIVID CLINICAL SERVICES PTY LTD

    lead INDUSTRY

Principal Investigators

  • Jian Wang · VIVID CLINICAL SERVICES PTY LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-05-14
Completion
2027-08-26

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07804628 on ClinicalTrials.gov